Vaccine development to treat alzheimer's disease neuropathology in APP/PS1 transgenic mice

International Journal of Alzheimer's Disease

Volumn , Issue , 2012, Pages

  Carrera, Iván ^a   Etcheverría, Ignacio ^a   Fernández Novoa, Lucía ^a   Lombardi, Valter ^a   Cacabelos, Ramón ^b   Vigo, Carmen ^c  

^a Polígono de Bergondo ^*  (Spain)

^b Centro de Investigacion Biomedica EuroEspes   (Spain)

^c Neuroscience Division Atlas Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; EB 101 VACCINE; IMMUNOLOGICAL ADJUVANT; LIPOSOME; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; ASTROCYTOSIS; BALANCE IMPAIRMENT; DRUG SYNTHESIS; IMAGING; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; MOTOR COORDINATION; MOUSE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 84867356027     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2012/376138     Document Type: Article

References (84)

1. Cacabelos R., Fernandez-Novoa L., Lombardi V., Kubota Y., Takeda M., Molecular genetics of Alzheimer's disease and aging. Methods and Findings in Experimental and Clinical Pharmacology 2005 27 1 573 2-s2.0-27744509435
2. Selkoe D. J., Toward a comprehensive theory for Alzheimer's disease. Hypothesis: alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid β -protein. Annals of the New York Academy of Sciences 2000 924 17 25 2-s2.0-0034516988 (Pubitemid 32050177)
3. Blennow K., de Leon M. J., Zetterberg H., Alzheimer's disease. The Lancet 2006 368 9533 387 403 2-s2.0-33746310315 10.1016/S0140-6736(06)69113-7 (Pubitemid 44108123)
4. Nunomura A., Hofer T., Moreira P. I., Castellani R. J., Smith M. A., Perry G., RNA oxidation in Alzheimer disease and related neurodegenerative disorders. Acta Neuropathologica 2009 118 1 151 166 2-s2.0-67349251839 10.1007/s00401-009-0508-1
5. Selkoe D. J., Toward a remembrance of things past: deciphering Alzheimer disease. Harvey lectures 2003 99 23 45 2-s2.0-23044489284
6. Cacabelos R., Pharmacogenomics in alzheimer's disease. Methods in Molecular Biology 2008 448 213 357 2-s2.0-43549101184 10.1007/978-1-59745-205-2- 10
7. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guldo T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P., Immunization with amyloid- β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999 400 6740 173 177 2-s2.0-0033536163 10.1038/22124 (Pubitemid 29327547)
8. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., Yednock T., Epitope and isotype specificities of antibodies to β -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proceedings of the National Academy of Sciences of the United States of America 2003 100 4 2023 2028 2-s2.0-0037452779 10.1073/pnas.0436286100 (Pubitemid 36254567)
9. Carty N. C., Wilcock D. M., Rosenthal A., Grimm J., Pons J., Ronan V., Gottschall P. E., Gordon M. N., Morgan D., Intracranial administration of deglycosylated C-terminal-specific anti-A β antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. Journal of Neuroinflammation 2006 3, article 11 2-s2.0-33745111586 10.1186/1742-2094-3-11 (Pubitemid 43885294)
10. Morgan D., Immunotherapy for Alzheimer's disease. Journal of Alzheimer's Disease 2006 9 supplement 3 425 432 2-s2.0-33747464397 (Pubitemid 44255489)
11. Mamikonyan G., Necula M., Mkrtichyan M., Ghochikyan A., Petrushina I., Movsesyan N., Mina E., Kiyatkin A., Glabe C. G., Cribbs D. H., Agadjanyan M. G., Anti-A β 1-11 antibody binds to different β -amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. The Journal of Biological Chemistry 2007 282 31 22376 22386 2-s2.0-34547955761 10.1074/jbc.M700088200 (Pubitemid 47267321)
12. Lemere C. A., Masliah E., Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nature Reviews Neurology 2010 6 2 108 119 2-s2.0-76849091134 10.1038/nrneurol.2009.219
13. Schenk D., Amyloid- β immunotherapy for Alzheimer's disease: the end of the beginning. Nature Reviews Neuroscience 2002 3 10 824 828 2-s2.0-0036780877 10.1038/nrn938 (Pubitemid 135706694)
14. Morgan D., Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. Neurochemistry International 2006 49 2 190 194 2-s2.0-33744982670 10.1016/j.neuint.2006.03.017 (Pubitemid 43867077)
15. Chen G., Chen K. S., Kobayashi D., Barbour R., Motter R., Games D., Martin S. J., Morris R. G. M., Active β -amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of β -amyloid. Journal of Neuroscience 2007 27 10 2654 2662 2-s2.0-33847776041 10.1523/JNEUROSCI.3710-06.2007 (Pubitemid 46393609)
16. Wilcock D. M., Gharkholonarehe N., Van Nostrand W. E., Davis J., Vitek M. P., Colton C. A., Amyloid reduction by amyloid- β vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. Journal of Neuroscience 2009 29 25 7957 7965 2-s2.0-67649363905 10.1523/JNEUROSCI.1339-09.2009
17. Fu H. J., Liu B., Frost J. L., Lemere C. A., Amyloid- β immunotherapy for Alzheimer's disease. CNS and Neurological Disorders Drug Targets 2010 9 2 197 206 2-s2.0-77949884626
18. Maier M., Seabrook T. J., Lazo N. D., Jiang L., Das P., Janus C., Lemere C. A., Short amyloid- β (A β) immunogens reduce cerebral A β load and learning deficits in an Alzheimer's disease mouse model in the absence of an A β -specific cellular immune response. Journal of Neuroscience 2006 26 18 4717 4728 2-s2.0-33646938005 10.1523/JNEUROSCI.0381-06.2006 (Pubitemid 44315311)
19. Dodart J. C., Bales K. R., Gannon K. S., Greene S. J., DeMattos R. B., Mathis C., DeLong C. A., Wu S., Wu X., Holtzman D. M., Paul S. M., Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model. Nature Neuroscience 2002 5 5 452 457 2-s2.0-0036240395 10.1038/nn842 (Pubitemid 34454251)
20. Kotilinek L. A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B. T., Younkin S., Ashe K. H., Reversible memory loss in a mouse transgenic model of Alzheimer's disease. Journal of Neuroscience 2002 22 15 6331 6335 2-s2.0-0036703483 (Pubitemid 35386387)
21. Orgogozo J. M., Gilman S., Dartigues J. F., Laurent B., Puel M., Kirby L. C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B. F., Boada M., Frank A., Hock C., Subacute meningoencephalitis in a subset of patients with AD after A β 42 immunization. Neurology 2003 61 1 46 54 2-s2.0-10744230547 (Pubitemid 36818745)
22. Nicolll J. A. R., Wilkinson D., Holmes C., Steart P., Markham H., Weller R. O., Neuropathology of human Alzheimer disease after immunization with amyloid- β peptide: a case report. Nature Medicine 2003 9 4 448 452 2-s2.0-0037393454 10.1038/nm840 (Pubitemid 36460079)
23. Ferrer I., Boada Rovira M., Sánchez Guerra M. L., Rey M. J., Costa-Jussá F., Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathology 2004 14 1 11 20 2-s2.0-1042265187 (Pubitemid 38200585)
24. Gilman S., Koller M., Black R. S., Jenkins L., Griffith S. G., Fox N. C., Eisner L., Kirby L., Boada Rovira M., Forette F., Orgogozo J. M., Clinical effects of A β immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005 64 9 1553 1562 2-s2.0-20944448555 10.1212/01.WNL. 0000159740.16984.3C (Pubitemid 40617691)
25. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., Schenk D., A β vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005 64 1 129 131 2-s2.0-19944429065 (Pubitemid 40082949)
26. Howlett D. R., APP transgenic mice and their application to drug discovery. Histology and Histopathology 2011 26 12 1611 1632 2-s2.0-80053987137
27. Ashe K. H., Zahs K. R., Probing the biology of Alzheimer's disease in mice. Neuron 2010 66 5 631 645 2-s2.0-77953675879 10.1016/j.neuron.2010.04.031
28. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagoplan S., Johnson-Wood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein. Nature 1995 373 6514 523 527 2-s2.0-0028985574
29. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G., Correlative memory deficits, A β elevation, and amyloid plaques in transgenic mice. Science 1996 274 5284 99 102 2-s2.0-0029742199 10.1126/science.274.5284.99 (Pubitemid 26332733)
30. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K. H., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P. A., Waridel C., Calhoun M. E., Jucker M., Probst A., Staufenbiel M., Sommer B., Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proceedings of the National Academy of Sciences of the United States of America 1997 94 24 13287 13292 2-s2.0-0011444914 10.1073/pnas.94.24.13287 (Pubitemid 27518514)
31. Mustafiz T., Portelius E., Gustavsson M. K., Hölttä M., Zetterberg H., Blennow K., Nordberg A., Unger Lithner C., Characterization of the brain β -amyloid isoform pattern at different ages of Tg2576 mice. Neurodegenerative Diseases 2011 8 5 352 363 2-s2.0-79958778139 10.1159/000323871
32. McGowan E., Sanders S., Iwatsubo T., Takeuchi A., Saido T., Zehr C., Yu X., Uljon S., Wang R., Mann D., Dickson D., Duff K., Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiology of Disease 1999 6 4 231 244 2-s2.0-0032886415 10.1006/nbdi.1999.0243 (Pubitemid 29470035)
33. Holcomb L., Gordon M. N., Mcgowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C. M., Eckman C., Younkin S., Hsiao K., Duff K., Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Medicine 1998 4 1 97 100 2-s2.0-0031914718 10.1038/nm0198-097 (Pubitemid 28133087)
34. Chishti M. A., Yang D. S., Janus C., Phinney A. L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P. E., Carlson G. A., George -. P. S., Westawaya D., Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. The Journal of Biological Chemistry 2001 276 24 21562 21570 2-s2.0-0035877756 10.1074/jbc.M100710200 (Pubitemid 37413154)
35. Gordon M. N., Holcomb L. A., Jantzen P. T., DiCarlo G., Wilcock D., Boyett K. W., Connor K., Melachrino J., O'Callaghan J. P., Morgan D., Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Experimental Neurology 2002 173 2 183 195 2-s2.0-0036175608 10.1006/exnr.2001.7754 (Pubitemid 34151370)
36. Jankowsky J. L., Fadale D. J., Anderson J., Xu G. M., Gonzales V., Jenkins N. A., Copeland N. G., Lee M. K., Younkin L. H., Wagner S. L., Younkin S. G., Borchelt D. R., Mutant presenilins specifically elevate the levels of the 42 residue β -amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. Human Molecular Genetics 2004 13 2 159 170 2-s2.0-1642555780 10.1093/hmg/ddh019 (Pubitemid 38111354)
37. Trinchese F., Liu S., Battaglia F., Walter S., Mathews P. M., Arancio O., Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Annals of Neurology 2004 55 6 801 814 2-s2.0-2542584749 10.1002/ana.20101 (Pubitemid 38702575)
38. Malm T., Koistinaho J., Kanninen K., Utilization of APPswe/PS1dE9 transgenic mice in research of Alzheimer's disease: focus on gene therapy and cell-based therapy applications. International Journal of Alzheimer's Disease 2011 2011 8 517160 2-s2.0-84855271475 10.4061/2011/517160
39. Maceyka M., Harikumar K. B., Milstien S., Spiegel S., Sphingosine-1-phosphate signaling and its role in disease. Trends in Cell Biology 2012 22 1 50 60 2-s2.0-84855303523
40. Guénette S. Y., Mechanisms of A β clearance and catabolism. NeuroMolecular Medicine 2003 4 3 147 160 2-s2.0-10744232186 10.1385/NMM:4:3:147 (Pubitemid 38049970)
41. Andreasen N., Sjögren M., Blennow K., CSF markers for Alzheimer's disease: total tau, phospho-tau and A β 42. World Journal of Biological Psychiatry 2003 4 4 147 155 2-s2.0-14644398469 10.1080/15622970310029912
42. Suo Z., Cox A. A., Bartelli N., Rasul I., Festoff B. W., Premont R. T., Arendash G. W., GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment. Neurobiology of Aging 2007 28 12 1873 1888 2-s2.0-35148836216 10.1016/j.neurobiolaging.2006.08.013 (Pubitemid 47539698)
43. Sun A., Nguyen X. V., Bing G., Comparative analysis of an improved thioflavin-S stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. Journal of Histochemistry and Cytochemistry 2002 50 4 463 472 2-s2.0-0036193799 (Pubitemid 34250585)
44. Bussière T., Bard F., Barbour R., Grajeda H., Guido T., Khan K., Schenk D., Games D., Seubert P., Buttini M., Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive A β immunotherapy on their clearance. American Journal of Pathology 2004 165 3 987 995 2-s2.0-4344565054 (Pubitemid 39129305)
45. Zhou J., Fonseca M. I., Kayed R., Hernandez I., Webster S. D., Yazan O., Cribbs D. H., Glabe C. G., Tenner A. J., Novel A peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. Journal of Neuroinflammation 2005 2, article 28 2-s2.0-29244461729 10.1186/1742-2094-2-28 (Pubitemid 41819440)
46. Jones M., Cordell J. L., Beyers A. D., Tse A. G. D., Mason D. Y., Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies. Journal of Immunology 1993 150 12 5429 5435 2-s2.0-0027300658 (Pubitemid 23180656)
47. Allison A. C., Cacabelos R., Lombardi V. R. M., Álvarez X. A., Vigo C., Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2001 25 7 1341 1357 2-s2.0-0034752311 10.1016/S0278-5846(01)00192-0 (Pubitemid 33022713)
48. Zhang W., Narayanan M., Friedlander R. M., Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Annals of Neurology 2003 53 2 267 270 2-s2.0-0037310563 10.1002/ana.10476 (Pubitemid 36164012)
49. Muhs A., Hickman D. T., Pihlgren M., Chuard N., Giriens V., Meerschman C., Van Der Auwera I., Van Leuven F., Sugawara M., Weingertner M. C., Bechinger B., Greferath R., Kolonko N., Nagel-Steger L., Riesner D., Brady R. O., Pfeifer A., Nicolau C., Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 2007 104 23 9810 9815 2-s2.0-34547473731 10.1073/pnas.0703137104 (Pubitemid 47175348)
50. Le Stunff H., Milstien S., Spiegel S., Generation and metabolism of bioactive sphingosine-1-phosphate. Journal of Cellular Biochemistry 2004 92 5 882 899 2-s2.0-14644391944 10.1002/jcb.20097 (Pubitemid 44264239)
51. Pyne S., Long J. S., Ktistakis N. T., Pyne N. J., Lipid phosphate phosphatases and lipid phosphate signalling. Biochemical Society Transactions 2005 33 6 1370 1374 2-s2.0-28844452498 10.1042/BST20051370 (Pubitemid 41779690)
52. Pilorget A., Annabi B., Bouzeghrane F., Marvaldi J., Luis J., Béliveau R., Inhibition of angiogenic properties of brain endothelial cells by platelet-derived sphingosine-1-phosphate. Journal of Cerebral Blood Flow and Metabolism 2005 25 9 1171 1182 2-s2.0-24944561984 10.1038/sj.jcbfm. 9600117 (Pubitemid 41715069)
53. Rosen H., Goetzl E. J., Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nature Reviews Immunology 2005 5 7 560 570 2-s2.0-21844457949 10.1038/nri1650 (Pubitemid 40961333)
54. Alvarez S. E., Milstien S., Spiegel S., Autocrine and paracrine roles of sphingosine-1-phosphate. Trends in Endocrinology and Metabolism 2007 18 8 300 307 2-s2.0-34948813594 10.1016/j.tem.2007.07.005 (Pubitemid 47531961)
55. Yatomi Y., Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. Current Pharmaceutical Design 2006 12 5 575 587 2-s2.0-33644916646 10.2174/138161206775474404
56. Hla T., Signaling and biological actions of sphingosine 1-phosphate. Pharmacological Research 2003 47 5 401 407 2-s2.0-0037401876 10.1016/S1043-6618(03)00046-X (Pubitemid 36379202)
57. Hla T., Brinkmann V., Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation. Neurology 2011 76 8 S3 S8 2-s2.0-79952027563 10.1212/WNL.0b013e31820d5ec1
58. Spiegel S., Milstien S., The outs and the ins of sphingosine-1-phosphate in immunity. Nature Reviews Immunology 2011 11 6 403 415 2-s2.0-79957610938 10.1038/nri2974
59. Kajimoto T., Okada T., Yu H., Goparaju S. K., Jahangeer S., Nakamura S. I., Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons. Molecular and Cellular Biology 2007 27 9 3429 3440 2-s2.0-34247552132 10.1128/MCB.01465-06 (Pubitemid 46685218)
60. Anelli V., Bassi R., Tettamanti G., Viani P., Riboni L., Extracellular release of newly synthesized sphingosine-1-phosphate by cerebellar granule cells and astrocytes. Journal of Neurochemistry 2005 92 5 1204 1215 2-s2.0-14844309632 10.1111/j.1471-4159.2004.02955.x (Pubitemid 40344310)
61. Kimura A., Ohmori T., Ohkawa R., Madoiwa S., Mimuro J., Murakami T., Kobayashi E., Hoshino Y., Yatomi Y., Sakata Y., Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 2007 25 1 115 124 2-s2.0-33846021925 10.1634/stemcells.2006-0223 (Pubitemid 46052981)
62. Lee S. S., Woo C. H., Chang J. D., Kim J. H., Roles of Rac and cytosolic phospholipase A2 in the intracellular signalling in response to titanium particles. Cellular Signalling 2003 15 3 339 345 2-s2.0-0037343290 10.1016/S0898-6568(02)00118-3 (Pubitemid 36071678)
63. Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., Schenk D. B., Characterization of β -amyloid peptide from human cerebrospinal fluid. Journal of Neurochemistry 1993 61 5 1965 1968 2-s2.0-0027379395 10.1111/j.1471-4159.1993.tb09841.x (Pubitemid 23317227)
64. Ruan L., Kang Z., Pei G., Le Y., Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease. Current Alzheimer Research 2009 6 6 531 540 2-s2.0-73949145739 10.2174/156720509790147070
65. Chauhan N. B., Intracerebroventricular passive immunization with anti-oligoA β antibody in TgCRND8. Journal of Neuroscience Research 2007 85 2 451 463 2-s2.0-33846861744 10.1002/jnr.21110 (Pubitemid 46219313)
66. Heneka M. T., Wiesinger H., Dumitrescu-Ozimek L., Riederer P., Feinstein D. L., Klockgether T., Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. Journal of Neuropathology and Experimental Neurology 2001 60 9 906 916 2-s2.0-0034836593 (Pubitemid 32880598)
67. Koistinaho M., Lin S., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K. R., Paul S. M., Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid- β peptides. Nature Medicine 2004 10 7 719 726 2-s2.0-3142781310 10.1038/nm1058 (Pubitemid 38937637)
68. Wyss-Coray T., Loike J. D., Brionne T. C., Lu E., Anankov R., Yan F., Silverstein S. C., Husemann J., Adult mouse astrocytes degrade amyloid- βin vitro and in situ. Nature Medicine 2003 9 4 453 457 2-s2.0-0037394788 10.1038/nm838 (Pubitemid 36460080)
69. Minkeviciene R., Ihalainen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., Iivonen H., Leguit N., Glennon J., Koistinaho J., Banerjee P., Tanila H., Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. Journal of Neurochemistry 2008 105 3 584 594 2-s2.0-42449107478 10.1111/j.1471-4159.2007.05147.x (Pubitemid 351562711)
70. Chakrabarty P., Herring A., Ceballos-Diaz C., Das P., Golde T. E., Hippocampal expression of murine TNF results in attenuation of amyloid deposition in vivo. Molecular Neurodegeneration 2011 6 1, article 16 2-s2.0-79951551206 10.1186/1750-1326-6-16
71. Shah S., Federoff H. J., Therapeutic potential of vaccines for Alzheimers disease. Immunotherapy 2011 3 2 287 298 2-s2.0-79951732094 10.2217/imt.10.94
72. Racke M. M., Boone L. I., Hepburn D. L., Parsadainian M., Bryan M. T., Ness D. K., Piroozi K. S., Jordan W. H., Brown D. D., Hoffman W. P., Holtzman D. M., Bales K. R., Gitter B. D., May P. C., Paul S. M., DeMattos R. B., Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β Journal of Neuroscience 2005 25 3 629 636 2-s2.0-19944431509 10.1523/JNEUROSCI.4337-04.2005
73. Boche D., Zotova E., Weller R. O., Love S., Neal J. W., Pickering R. M., Wilkinson D., Holmes C., Nicoll J. A. R., Consequence of A β immunization on the vasculature of human Alzheimer's disease brain. Brain 2008 131 12 3299 3310 2-s2.0-58149129243 10.1093/brain/awn261
74. Monsonego A., Imitola J., Petrovic S., Zota V., Nemirovsky A., Baron R., Fisher Y., Owens T., Weiner H. L., A β -induced meningoencephalitis is IFN- γ -dependent and is associated with T cell-dependent clearance of A β in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2006 103 13 5048 5053 2-s2.0-33645517069 10.1073/pnas.0506209103
75. Weiner H. L., Frenkel D., Immunology and immunotherapy of Alzheimer's disease. Nature Reviews Immunology 2006 6 5 404 416 2-s2.0-33646384419 10.1038/nri1843
76. Kitazawa M., Oddo S., Yamasaki T. R., Green K. N., LaFerla F. M., Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. Journal of Neuroscience 2005 25 39 8843 8853 2-s2.0-25644456097 10.1523/JNEUROSCI.2868-05.2005 (Pubitemid 41384452)
77. Cribbs D. H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., Babikyan D., Kesslak P., Kieber-Emmons T., Cotman C. W., Agadjanyan M. G., Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β -amyloid. International Immunology 2003 15 4 505 514 2-s2.0-0037384333 10.1093/intimm/dxg049 (Pubitemid 36432403)
78. Vasilevko V., Xu F., Previti M. L., Van Nostrand W. E., Cribbs D. H., Experimental investigation of antibody-mediated clearance mechanisms of amyloid- β in CNS of Tg-SwDI transgenic mice. Journal of Neuroscience 2007 27 49 13376 13383 2-s2.0-37149008108 10.1523/JNEUROSCI.2788-07.2007 (Pubitemid 350255342)
79. Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., Morgan T. E., Rozovsky I., Trommer B., Viola K. L., Wals P., Zhang C., Finch C. E., Krafft G. A., Klein W. L., Diffusible, nonfibrillar ligands derived from A β 1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences of the United States of America 1998 95 11 6448 6453 2-s2.0-11544279355
80. Boutajangout A., Quartermain D., Sigurdsson E. M., Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. Journal of Neuroscience 2010 30 49 16559 16566 2-s2.0-78650065372 10.1523/JNEUROSCI.4363-10.2010
81. DeMattos R. B., Bales K. R., Cummins D. J., Dodart J. C., Paul S. M., Holtzman D. M., Peripheral anti-A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2001 98 15 8850 8855 2-s2.0-0035902619 10.1073/pnas.151261398 (Pubitemid 32678116)
82. Vollmar P., Kullmann J. S., Thilo B., Claussen M. C., Rothhammer V., Jacobi H., Sellner J., Nessler S., Korn T., Hemmer B., Active immunization with amyloid- β 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system. Journal of Immunology 2010 185 10 6338 6347 2-s2.0-78650693417 10.4049/jimmunol.1001765
83. Cacabelos R., Pharmacogenomics in alzheimer's disease. Methods in Molecular Biology 2008 448 213 357 2-s2.0-43549101184 10.1007/978-1-59745-205-2- 10
84. Cacabelos R., Pharmacogenomics and therapeutic strategies for dementia. Expert Review of Molecular Diagnostics 2009 9 6 567 611 2-s2.0-70049083263 10.1586/erm.09.42